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BACKGROUND: Many clinical trials have demonstrated the effectiveness of gabapentin and 
pregabalin administration in the perioperative period as an adjunct to reduce acute postoperative 
pain. However, very few clinical trials have examined the use of gabapentin and pregabalin for the 
prevention of chronic postsurgical pain (CPSP). We (1) systematically reviewed the published 
literature pertaining to the prevention of CPSP (2 months after surgery) after perioperative 
administration of gabapentin and pregabalin and (2) performed a meta-analysis using studies 
that report sufficient data. A search of electronic databases (Medline, Embase, Cochrane Central 
Register of Controlled Trials, Cochrane Database of Systematic Reviews, IPA, and CINAHL) for 
relevant English-language trials to June 2011 was conducted.
METHODS: The following inclusion criteria for identified clinical trials were used for entry into the 
present systematic review: randomization; double-blind assessments of pain and analgesic use; 
report of pain using a reliable and valid measure; report of analgesic consumption; and an 
absence of design flaws, methodological problems or confounders that render interpretation of 
the results ambiguous. Trials that did not fit the definition of  preventive analgesia and did not 
assess chronic pain at 2 or more months after surgery were excluded.
RESULTS: The database search yielded 474 citations. Eleven studies met the inclusion criteria. 
Of the 11 trials, 8 studied gabapentin, 4 of which (i.e., 50%) found that perioperative 
administration of gabapentin decreased the incidence of chronic pain more than 2 months after 
surgery. The 3 trials that used pregabalin demonstrated a significant reduction in the incidence 
of CPSP, and 2 of the 3 trials also found an improvement in postsurgical patient function. Eight 
studies were included in a meta-analysis, 6 of the gabapentin trials demonstrated a moderate-
to-large reduction in the development of CPSP (pooled odds ratio [OR] 0.52; 95% confidence 
interval [CI], 0.27 to 0.98; P  0.04), and the 2 pregabalin trials found a very large reduction in 
the development of CPSP (pooled OR 0.09; 95% CI, 0.02 to 0.79; P  0.007). 
CONCLUSIONS: The present review supports the view that perioperative administration of 
gabapentin and pregabalin are effective in reducing the incidence of CPSP. Better-designed and 
appropriately powered clinical trials are needed to confirm these early findings.
The development of chronic postsurgical pain (CPSP)is an unfortunate consequence of surgery that ad-versely impacts the patient’s quality of life. Efforts to
prevent the establishment of CPSP include perioperative
administration of a variety of drugs. We systematically
reviewed the published literature pertaining to the preven-
tion of CPSP after perioperative interventions using gaba-
pentin and pregabalin. After defining preventive analgesia
we present the results of the systematic review and meta-
analysis, followed by a discussion of the results, including
the limitations of the current literature and future direc-
tions for clinical trials. Finally, we provide an overview of
recent basic science studies that suggest novel mechanisms
that may be responsible for some of the behavioral prop-
erties of gabapentin and pregabalin.
The factors that influence the transition from acute
postoperative pain to CPSP have yet to be elucidated. CPSP
has been defined as pathological pain that persists for
longer than 2 months after surgery.1 Several patient-related
and surgical factors have been linked to the development of
CPSP.2 The most consistent patient factor is the presence
and/or intensity of preoperative and postoperative pain.3–5
Because moderate to severe postoperative pain is a fre-
quent occurrence after surgery,6 novel drugs such as gaba-
pentin and pregabalin in addition to traditional opioids are
administered with the aim of providing superior pain relief
at rest and with movement, reducing opioid consumption
and reducing analgesic-related adverse effects.7–9 If drugs,
such as gabapentin and pregabalin, can prevent the estab-
lishment of surgery-induced central sensitization and can
decrease postoperative pain,10–12 then these drugs, given
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during the perioperative period, may also play a role in
preventing the transition of acute pain to chronic pain.13,14
Neuropathic pain, which is defined as pain initiated or
caused by a primary lesion or dysfunction in the nervous
system,15 has been implicated as a major contributor to the
development of CPSP.2,16 Given that both gabapentin and
pregabalin are front-line treatments for patients suffering
from established chronic neuropathic pain,17,18 it is plausible
that these drugs, when used in the perioperative setting, may
be of benefit in reducing the incidence and/or intensity of
chronic pain.
PREVENTIVE ANALGESIA
Preventive analgesia has evolved from preemptive analgesia
by shifting the focus from blocking solely noxious preopera-
tive stimuli12,19–21 to a broader conceptualization involving
blocking noxious stimuli across the entire perioperative pe-
riod.13,14,22 A preventive analgesic effect is demonstrated
when postoperative pain and/or analgesic consumption is
reduced in relation to an intervention, as long as the effect is
observed at a time that exceeds the expected clinical duration
of action of the target drug. We have defined a preventive
analgesic effect as one that is demonstrated when postopera-
tive pain and/or analgesic use are reduced beyond 5.5 half-
lives of the target drug.12,13,22 This requirement ensures that
the observed effects are not direct analgesic effects.12,13
GABAPENTIN (NEURONTIN, PFIZER, INC.) AND
PREGABALIN (LYRICA, PFIZER, INC.)
Gabapentin, a structural analog of -aminobutyric acid
(GABA), was initially used as an anticonvulsant in the late
1980s. Clinically, gabapentin demonstrated poor efficacy as
an anticonvulsant.23 The antinociceptive properties of this
drug, along with the advantage of producing only mild
side effects, made gabapentin an attractive therapeutic
option for pain specialists who used other anticonvulsants
with significant adverse events (i.e., carbamazepine) for
chronic pain conditions.23 By the late 1990s, gabapentin had
become a first-line treatment for patients who suffered
from chronic neuropathic pain.24,25 In recent years, gabap-
entin has been used widely as an adjunct for the treatment
of acute postsurgical pain. Several meta-analyses have
confirmed the efficacy of gabapentin in reducing postop-
erative opioid use and pain.26–28
Pregabalin is structurally similar to gabapentin and was
also marketed primarily for epilepsy and neuropathic pain.
Pregabalin (S-[]-3-isobutylgaba) was designed as a
lipophilic GABA analog substituted at the 3 position to
facilitate diffusion across the blood–brain barrier.29,30 Pre-
gabalin has also been found to be effective at reducing
acute postoperative pain.10,31–36
Studies have reported the effects of the gabapentinoids
in the prevention of CPSP. We systematically reviewed the
published, clinical trials pertaining to the prevention of
CPSP (2 months after surgery) after perioperative inter-
ventions using gabapentin and pregabalin.
METHODS
Search Strategy
A search strategy was developed using the Medline database
and subsequently translated into the remaining databases.
The following databases were searched: Medline, Embase,
Cochrane Central Register of Controlled Trials, Cochrane
Database of Systematic Reviews, International Pharmaceuti-
cal Abstracts (IPA, accessed via the OvidSP platform) and
Cumulative Index to Nursing & Allied Health Literature
(CINAHL, accessed via the EbscoHost platform). The search
strategy contained 3 components: pregabalin or gabapentin
terms, including generic and trade names, chemical abstract
service (CAS) registry numbers, MeSH or Emtree or text
words; preemptive, preventive, or perioperative terms, using
MeSH or Emtree or text words; and finally, chronic pain
terms, using MeSH or Emtree or text words (Appendix 1).
These 3 components were combined using the Boolean op-
erator, “AND,” to obtain the intersection of the 3 sets; the
results were limited to human subjects and English-language
articles. All databases were searched in their entirety to the
end of June 2011; however, the Embase database was limited
to searches from 2006 to 2011.
Inclusion Criteria
All clinical trials were evaluated according to the following
inclusion criteria for entry into the present review: random-
ized assignment of patients to treatment groups; double-blind
assessments of pain and analgesic use; report of pain using a
reliable and valid measure; report of analgesic consumption;
and an absence of design flaws, methodological problems, or
confounders that render interpretation of the results ambigu-
ous.22 Trials that did not fit the definition of preventive
analgesia14 and did not assess chronic pain at 2 or more
months after surgery were excluded.
Data Extraction
Two reviewers (H.C. and J.K.) independently reviewed the
abstracts of each reference identified by the above search
strategy, independently evaluated each included study for
content, and completed a data extraction table that in-
cluded relevant data. Studies were included if both review-
ers agreed that the studies met the inclusion criteria.
Assessment of the Methodological Quality and
Risk of Bias
Two reviewers (H.C. and J.K.) independently assessed the
methodological quality of the included trials according to
the Delphi criteria list.38 The Delphi list identifies 9 criteria
for quality assessment (Table 1).
Statistical Analysis
Meta-analysis was used to calculate pooled effects of gabap-
entin or pregabalin on the development of chronic pain at 3 to
6 months after surgery. For cases in which a study reported
the rates of chronic pain development of chronic pain at both
3 and 6 months, we included only 6-month event rates in the
statistical analysis. Summary effects were expressed as pooled
odds ratios (OR) with associated 95% confidence intervals
(CI). Initially, statistical heterogeneity was assessed using the
I2 statistic,39,40 which describes the proportion of total varia-
tion explained by between-studies variation instead of chance.
Higher I2 statistics imply more heterogeneity between studies
than would be expected by chance alone. In the presence of
low heterogeneity (I2  25%), pooled ORs were calculated
under the fixed-effects model; otherwise, the random-effects
model was used. In addition, a subgroup analysis based on
the drug administered was performed, with a statistical
test-of-interaction being used to assess for subgroup differ-
ences. Finally, funnel plots41 and the test of Harbord et al.42
were used to test for any publication bias.
Statistical significance was defined by a 2-sided P value
0.05, and all analyses were performed using Stata Version
11.2 (StataCorp Inc., College Station, TX). Our review
complies with the guidelines set forth by the Preferred
Reporting Items for Systematic Reviews and Meta-Analysis
(PRISMA).43,44
RESULTS
Search Results
The database search yielded 474 citations, of which 64
studies were retrieved and examined; 11 studies met the
inclusion criteria (Fig. 1).31,34,45–53
Assessment of Methodological Quality
Table 1 summarizes the assessment of methodological
quality of the 11 clinical trials. All studies were double-
blind, randomized, controlled trials with specified eligibil-
ity criteria listed. Outcome assessors were blinded in all
studies. Only 1 study reported an intention-to-treat analysis
for postoperative outcomes.31
Study Characteristics
The 11 studies are summarized in Table 2. The studies
examined the preventive effects of gabapentin or pregaba-
lin on CPSP (2 months after surgery) and were published
between October 2002 and June 2011. A total of 930 patients
were included in the trials. The sample sizes ranged from
n  30 to n  240, with a median of n  50. The surgical
populations studied were as follows: breast surgery,46,51,52
total knee arthroplasty,31 total hip arthroplasty,49 cesarean
delivery,45 thyroidectomy,50 cardiac surgery,53 lumbar
discectomy,34 inguinal herniorraphy,47 and abdominal hys-
terectomy.48 Eight trials studied the effects of gabapen-
tin,45–52 and 3 trials studied the effects of pregabalin31,34,53
on the prevention of pain that persisted for at least 2
months after surgery.
The clinical heterogeneity is considerable among the 11
trials presented in this systematic review and meta-analysis.
The studies using gabapentin varied with respect to the
dosing regimen and the perioperative administration. Five of
the 8 gabapentin studies administered a single preoperative
dose of gabapentin,45,47–50 3 studies used a single preopera-
tive dose of 1200 mg,47,48,50 and the 2 other studies used a
single 600-mg preoperative dose.45,49 The remaining 3 studies
started gabapentin administration before surgery and contin-
ued either 1200mg of gabapentin daily for 8 or 10 days,51,52 or
300 mg for 10 days postoperatively.46 Finally, the pregabalin
studies were also variable with respect to the timing and
Figure 1. Selection process for systematic review.
Table 1. Methodological Quality Assessment
Study Randomization
Treatment
allocation
concealed?
Similar
groups at
baseline?
Specified
eligibility
criteria?
Outcome
assessor
blinded?
Care
provider
blinded?
Patient
blinded?
Point estimates
of variability for
primary outcome
measures?
Intention-
to-treat
analysis for
postoperative
outcomes?
Total
quality
score/9
Amr et al. (2010)46 Y Y Y Y Y Y Y N N 7
Buvanendran et al. (2010)31 Y Y Y Y Y Y Y Y Y 9
Brogly et al. (2008)50 Y Y Y Y Y ? Y N N 6
Burke et al. (2010)34 Y Y Y Y Y Y Y Y N 8
Clarke et al. (2009)49 Y Y Y Y Y Y Y Y N 8
Fassoulaki et al. (2002)51 Y Y Y Y Y Y Y N N 7
Fassoulaki et al. (2005)52 Y Y Y Y Y Y Y N N 7
Moore et al. (2011)45 Y Y Y Y Y Y Y Y N 8
Pesonen et al. (2011)53 Y Y Y Y Y Y Y Y N 8
Sen et al. (2009)48–
hysterectomy
Y Y Y Y Y ? Y Y N 7
Sen et al. (2009)47–
hernia
Y Y Y Y Y Y Y Y N 8
Note: The listed criterion are taken from the Delphi consensus for quality assessment of randomized clinical trials.
A higher score indicates higher study quality. ?  Not reported; N  No; NA  not applicable; Y  Yes.
Table 2. Study Characteristics
Study Design and sample Intervention Outcome measuresintravenous
Measurement
time points
Amr et al.
(2010)46
Date: NR
Design: 3 group RCT
N  150 (Ven: n  50; Gpn:
n  50; C: n  50)
Sample characteristics: Low-risk
patients ASA 1 and 2
scheduled for either partial or
radical mastectomy
Mean age (SD): Ven  45
years (6); Gpn  43 years
(5); C  44 years (8)
Perioperative intervention
RCT: Breast surgery
F: (G1) oral Ven 37.5 mg/day
started the night before surgery
and continued for 10 days
(G2) oral Gpn 300 mg/day started
the night before surgery and
continued for 10 days
(G3) placebo
Primary outcome: Postop opioid
consumption
Secondary outcomes: Pain scores
perioperatively and daily until
10 days postop
Chronic pain outcomes
T1  daily pain
scores and
opioid
consumption
until postop day
10
T2  6 months
postop
Brogly et al.
(2008)50
Date: May–November 2006
Design: RCT
N  50 (Gpn: n  22; C:
n  21)
Sample characteristics: ASA I–III
patients scheduled for total
or partial thyroidectomy
without lymph node
dissection
Mean age (range): Gpn 
49 (18–63) C  49 (25–72)
Perioperative intervention
RCT: effect of Gpn after thyroid
surgery with SCPB
F: (G1) oral Gpn 1200 mg given 2
hours before surgery
(G2) placebo
All patients received a SCPB
Primary outcome: Postop rescue
analgesic use after
thyroidectomy with SCPB
Secondary outcomes: Chronic
neuropathic pain outcomes
T1  0–24 hours
postop
T2  6 months
postop
Burke et al.
(2010)34
Date: NR
Design: RCT
N  40 (Pregab: n  20; C:
n  20)
Sample characteristics: Low-
risk (ASA 1 and 2) patients
with chronic lumbar sacral
radiculopathy undergoing
elective lumbar discectomy
Mean age: Pregab  37
years (7.8); C  41
years (12.4)
Perioperative intervention
RCT: Effect of Pregab on pain and
functional outcomes 3 months
after discectomy
F: (G1) oral Pregab 300 mg given
90 minutes before surgery
followed by 150 mg at 12 and
24 hours postoperatively
(G2) placebo
Primary outcome: Change in pain
intensity as measured by a
visual analogue scale (VAS,
0–100 mm) from the
preoperative assessment to the
3- month follow-up
Secondary outcomes: Preoperative
anxiolysis, disability measures,
health- related quality-of-life
measures, quantitative sensory
testing assessments (i.e., pain
sensation thresholds), and DNA
analysis of CGH1 and OPRM1
T1  baseline
T2  24 hours
postop
T3  3 months
postop
Buvanendran
et al.
(2010)31
Date: August 2006 to August
2007
Design: RCT
N  240 (Pregab: n  120;
C: n  120)
Sample characteristics: ASA I–III
patients scheduled for total
knee arthroplasty
Mean age: Pregab  64
years (8.3); C  63.3
years (8.9)
Perioperative intervention
RCT: Effect of Pregab on pain after
total knee arthroplasty
F: (G1) oral Pregab 300 mg before
surgery and pregab 50–150 mg
daily and for 14 days after total
knee arthroplasty
(G2) placebo
Primary outcome: A reduction in
the incidence of neuropathic
pain at 6 months for the
Pregab-treated group
Secondary outcomes: Pain scores
perioperatively. Opioid
consumption and adverse
events
Active knee flexion 3 days postop,
sleep disturbance
T1  perioperative
to postop day 3
T2  1 month
postop
T3  3 months
postop
T4  6 months
postop
Clarke et al.
(2009)49
Date: May 2006 to April 2008
Design: 3 group RCT
N  126 (Preop Gpn: n  38;
postop Gpn: n  38; C:
n  38)
Sample characteristics: ASA I–III
patients scheduled for total
primary hip arthroplasty
Mean age (SD): Preop
Gpn  58.9 years (9.4);
postop Gpn  60.4
years (8.1); C  61.3
years (10.7)
Perioperative intervention
RCT: Gpn after total hip
arthroplasty
F: (G1) preemptive oral Gpn 600
mg given 2 hours before surgery
(G2) oral Gpn 600 mg given in
PACU immediately after surgery
(G3) placebo
All patients received a robust
perioperative multimodal pain
regimen that consisted of
acetaminophen, celecoxib,
dexamethasone, and spinal
anesthesia
Primary outcome: Opioid
consumption and pain scores
at rest and with movement to
48 hours
Secondary outcomes: Incidence and
severity of chronic pain 6 months
post surgery. Psychosocial
Questionnaire Hip Arthroplasty
Pain questionnaire, Neuropathic
Pain Scale, The Hospital Anxiety
and Depression Scale
T1  48 hours
postop
T2  6 months
postop
(Continued)
Table 2. (Continued)
Study Design and sample Intervention Outcome measuresintravenous
Measurement
time points
Fassoulaki
et al.
(2002)51
Date: NR
Design: 3 group RCT
N  75 (Mexil: n  21; Gpn:
n  22; C: n  24)
Sample characteristics: Low-risk
patients ASA 1 and 2
scheduled for breast cancer
surgery
Mean age (SD)
Mexil  46 years (5); Gpn  42
years (7); C  45 years (10)
Perioperative intervention
RCT: Breast surgery
F: (G1) oral Mexil 600 mg/day
started the night before surgery
and continued for 10 days
(G2) oral Gpn 1200 mg/day started
the night before surgery and
continued for 10 days
(G3) placebo
Primary outcomes: Supplemental
analgesic consumption until
postop day 10. Pain scores at
rest and with movement until
postop day 10
Secondary outcomes: Incidence
and severity of chronic pain 3
months postsurgery. The use of
supplemental analgesics 3
months after surgery
T1  periop to
postop day 10
T2  3 months
postop
Fassoulaki
et al.
(2005)52
Date: March 2001 to January
2004
Design: RCT
N  50 (Gpn: n  25; C:
n  25)
Sample characteristics: Low-risk
patients ASA 1 and 2
scheduled for breast cancer
surgery
Mean age (SD): Gpn  49
years (8.4); C  48
years (8.1)
Perioperative intervention
RCT: Effect of multimodal
analgesia and Gpn on acute
and chronic pain after breast
cancer surgery
F: (G1) Gpn 400 mg every 6
hours, starting the evening
before surgery (18:00) and
continued until the eighth
postop day. 20 g of EMLA
cream (2.5% of lidocaine and
2.5% of prilocaine) was applied
to the wound area from the day
of surgery until the third postop
day. Intraoperatively, irrigation
of the brachial plexus and the
third, fourth, and fifth
intercostal spaces were
performed with 10 mL of 0.75%
ropivacaine (G2) placebo
Primary outcomes: Supplemental
analgesic consumption until
postop day 8. Pain scores at
rest and with movement until
postop day 8
Secondary outcomes: Incidence
and severity of chronic pain 3
and 6 months postsurgery. The
use of supplemental analgesics
3 and 6 months after surgery
T1  periop to
postop day 10
T2  3 months
postop
T3  6 months
postop
Moore et al.
(2011)45
Date: November 2007 to
November 2008
Design: RCT
N  46 (Gpn: n  23; C:
n  23)
Sample characteristics: Low-risk
patients ASA 1 and 2
undergoing elective caesarian
delivery
Mean age (SD): Gpn  35
years (5); C  34 years (6)
Perioperative intervention
RCT: Effect of Gpn after elective
caesarian delivery
F: (G1) oral Gpn 600 mg given 2
hours before surgery (G2)
placebo
Primary outcomes: Postop pain
scores at rest and with
movement 24 hours after
surgery
Secondary outcomes:
Supplemental analgesics and
side effects 24 hours after
surgery. Incidence and severity
of chronic pain 3 months
postsurgery
T1  24 hours
postop
T2  3 months
postop
Pesonen
et al.
(2011)53
Date: April 2008 to September
2009
Design: RCT
N  70 (Pregab: n  35; C:
n  35)
Sample characteristics: elderly
patients 75 years of age
scheduled to undergo primary
CABG with CPB or single-valve
repair or replacement with
CPB
Mean age: Pregab  79.5
years (75–89); C  69.6
years (75–91)
Perioperative intervention
RCT: effect of Pregab on elderly
patients after cardiac surgery
F: (G1) oral Pregab 150 mg before
surgery and Pregab 75 mg twice
daily and for 5 days after cardiac
surgery
(G2) placebo
Primary outcomes: Mean
parenteral oxycodone
consumption until 48 hours
after surgery
Secondary outcomes: Pain scores,
sedation, confusion, and
nausea and vomiting rates after
surgery. Incidence and severity
of chronic pain 1 and 3 months
postsurgery
T1  48 hours
postop
T2  1 month
postop
T3  3 months
postop
(Continued)
dosing administered. Two studies gave a 300-mg preopera-
tive dose and either continued the drug for 2 more doses (150
mg at 12 hours and 24 hours after surgery)34 or continued a
regimen of 50 to 150 mg of pregabalin daily for 2 weeks after
surgery.31 The third pregabalin trial gave a single preopera-
tive dose of 150 mg followed by 75 mg of pregabalin twice
daily for 5 days after surgery.53
Eight of the included trials31,45,46,49–53 reported sufficient
data for inclusion in a meta-analysis, the results of which are
presented in Figure 2. There was moderate overall statistical
heterogeneity (I2  36.6%), which was explained in part by
the specific drug administered. Specifically, heterogeneity
was lower within the subgroups of gabapentin (I2  30.5%)
and pregabalin studies (I2  0%). There was statistical evi-
dence (P  0.05) of different effects across the 2 subgroups
(Fig. 2). Notably, funnel plots of the 8 studies included in the
meta-analysis suggest a publication bias (Fig. 3); this raises the
possibility that several negative trials of gabapentin or prega-
balin have not been published. This possibility of publication
bias was supported by formal statistical testing that bordered
on significance (P  0.051).
Preventive Effects of Gabapentin on CPSP
Of the 8 gabapentin trials, 447,48,50,52 reported that the
perioperative use of gabapentin resulted in a lower inci-
dence of pain and/or lower analgesic requirements at
long-term follow-up (2 months after surgery) (Table 3).
Brogly et al.50 administered 1200 mg of gabapentin (n 25)
or placebo (n  25) 2 hours before total thyroidectomy
surgery. Patients also received superficial cervical plexus
blocks; a significant difference in opioid consumption or
pain scores was not observed during the first 24 hours after
surgery.50 Using the neuropathic pain diagnostic question-
naire (DN2) as a diagnostic tool, Brogly et al.50 found that
30% (7 of 24) of patients reported neuropathic pain in the
placebo group in comparison with 4% (1 of 23) of
gabapentin-treated patients at 6 months after surgery.
Using a similar design (i.e., 1200 mg gabapentin (n 
30) 1 hour before inguinal herniorrhaphy with spinal
anesthesia), Sen et al.47 reported that patients who
received gabapentin had less intense pain at 1, 3, and 6
months after surgery. The gabapentin-treated patients
reported less interruption with their activities of daily
living 1 month postsurgery.47
In another study by Sen et al.,48 40 women were randomly
assigned to receive placebo (n  20) versus intraoperative
ketamine until the end of surgery (n  20) versus 1200 mg
gabapentin 1 hour before total abdominal hysterectomy. Pa-
tients who received gabapentin had lower pain scores and
consumed fewer opioids in the acute postoperative period (24
hours). The incidence of incisional pain and pain intensity at
1, 3, and 6 months after surgery was significantly lower in the
gabapentin group than in the ketamine and control groups.48
Finally, Fassoulaki et al.52 found a reduction in pain and
analgesic consumption using a multimodal analgesic regi-
men, which involved 50 women who underwent breast
cancer surgery and were randomly assigned to receive 1200
mg gabapentin (for 8 postoperative days) starting the evening
before surgery, a eutectic mixture of local anesthetic cream
(for 3 postoperative days), and ropivacaine in the wound (at
wound closure) (n  25) and were compared with placebo
Table 2. (Continued)
Study Design and sample Intervention Outcome measuresintravenous
Measurement
time points
Sen et al.
(2009)48
Date: NR
Design: 3 group RCT
Design: 3 group RCT
N  60 (Ket: n  20; Gpn:
n  20; C: n  20)
Sample characteristics: Women
undergoing total abdominal
hysterectomy
Mean age (SD): Ket  46
years (6); Gpn  47
years (7); C  46 years (7)
Perioperative intervention
RCT: A comparison of intraoperative
ketamine infusion to preemptive
Gpn for total abdominal
hysterectomy
F: (G1) Ket 0.3 mg/kg intravenous
bolus before incision and 0.05
mg/kg/h infusion until the end of
surgery
(G2) oral Gpn 1200 mg given 1
hour before surgery
(G3) placebo
Primary outcome: Pain scores in
the supine and sitting positions
until 24 hours after surgery
Secondary outcomes: Intravenous
patient-controlled analgesia
morphine consumption up to 24
hours after surgery. Incidence
and severity of incisional pain
1, 3, and 6 months postsurgery
T1  24 hours
postop
T2  1 month
postop
T3  3 months
postop
T3  3 months
postop
T4  6 months
postop
Sen et al.
(2009)47
Date: November 2007 to
November 2008
Location: Istanbul, Turkey
Design: RCT
N  59 (Gpn: n  30;
C: n  29)
Sample characteristics: Low-risk
patients ASA 1 male patients
undergoing inguinal hernia
repair
Mean age (SD): Gpn  24
years (5.5); C  24
years (5.3)
Perioperative intervention
RCT: Effect of Gpn after inguinal
herniorrhaphy
F: (G1) oral Gpn 1200 mg given 1
hour before surgery
(G2) placebo
Primary outcomes: Postop pain
scores at rest and with
movement 24 hours after
surgery
Secondary outcomes:
Supplemental analgesics and
side effects 24 hours after
surgery. Incidence and severity
of chronic pain 1, 3, and 6
months postsurgery
T1  24 hours
postop
T2  1 month
postop
T3  3 months
postop
T4  6 months
postop
ASA  American Society of Anesthesiologists; CABG  coronary artery bypass graft; C  control; CPB  cardiopulmonary bypass; EMLA  eutectic mixture of
local anesthetics; F  frequency of treatment; G1  group 1; G2  group 2; G3  group 3; Gpn  gabapentin; Ket  ketamine; Mexil  mexiletine; NR  not
recorded; Postop  postoperative; Pregab  pregabalin; Preop  preoperative; RCT  randomized controlled trial; SCPB  superficial cervical plexus block;
SD  standard deviation; T  time point; Ven  venlafaxine; VAS  visual analogue scale.
(n  25).52 The group that received the multimodal analgesic
regimen used significantly less paracetamol and adjunctive
pain medications than did controls; they also reported lower
pain scores at rest and with movement on early postoperative
days. At 3 months after surgery, the patients who were in the
multimodal analgesia group reported a significantly lower
incidence of chronic pain (82% versus 45%) and used fewer
supplemental analgesics (23% versus 0%) than did patients
who received only placebo. Six months after surgery, 57% of
control patients complained of chronic pain in comparison
with 30% in the treatment group; however, this was not a
statistically significant finding.
The remaining 4 studies reported no effect of gabap-
entin on pain or supplemental analgesic use more than 2
months after surgery45,46,49,51 (Table 3). A closer exami-
nation of 2 of the negative gabapentin studies46,51
showed that, although there was no difference in the
incidence or severity of CPSP after breast cancer surgery
at the 3-month and 6-month follow-ups, both studies
found that patients who received gabapentin reported
less burning pain at these time points. Table 4 shows the
odds ratios comparing placebo-treated patients with
gabapentin- or pregabalin-treated patients with respect to the
Figure 2. Effects of gabapentin or pregabalin on the development of chronic pain at 3 to 6 months after surgery, stratified by the specific drug
administered. The pooled effect is expressed as a pooled odds ratio (OR) with associated 95% confidence intervals (CI). The shaded squares
represent point estimates in individual randomized controlled trials. The area of each square correlates with its contribution towards the pooled
summary estimates. Horizontal lines denote 95% CIs. The open diamonds represent the pooled estimates for all studies, as well as the 2
subgroups. The statistical heterogeneity, as measured by the I2 statistic, was 36.6% for the overall analysis, 30.5% for the gabapentin
subgroup, and 0% for the pregabalin subgroup. There was borderline statistical evidence (P  0.05) of a difference between the pooled
estimates in the gabapentin and pregabalin subgroups.
Figure 3. Funnel plot to assess for publication bias. Funnel plot41 of
the effect size from each study (expressed as the natural logarithm
of the odds ratio) against a measure of result precision from each
trial (expressed as the SE of the log odds ratio). The asymmetry of
the plot was suggestive of publication bias, which was further
confirmed through formal testing (P  0.051) using the method of
Harbord et al.42
Table 3. Postoperative Results for Specified Outcomes
Outcome Study
Quality/
Delphi
score
2 agent/
preventive effects Postoperative outcome results*(P < 0.05)
Chronic postsurgical
pain
Amr et al. (2010)46 7 Gabapentin, no Venlafaxine demonstrated a greater preventive effect
with respect to decreasing chronic pain versus
placebo-treated patients (i.e., less burning and
stabbing/pricking pain) at 6 months. Patients who
received gabapentin reported less burning than
control patients
Brogly et al. (2008)51 6 Gabapentin, yes Significantly more patients in the placebo group (7
out of 24, 30%) fit the DN2 criterion for chronic
neuropathic pain than did the patients who
received gabapentin after thyroid surgery with
SCPB (1 out of 23, 4.3%) 6 months after surgery
Burke et al. (2010)34 8 Pregabalin, yes Results demonstrated that the (mean  SD)
decrease in the VAS pain score at 3 months was
greater in patients who received
pregabalin (37.6  19.6 mm) than those who
received placebo (25.3  21.9 mm) (P  0.08)
Buvanendran et al. (2010)31 9 Pregabalin, yes Neuropathic pain was absent in the treatment
group (0%) versus placebo (8.7%) 3 months after
total knee arthroplasty surgery and again 0% in
the treatment group versus 5.2% in the placebo
group 6 months after surgery
Clarke et al. (2009)49 8 Gabapentin, no 6 months after total hip athroplasty surgery, the
incidence and severity of chronic postsurgical pain
was similar in all groups
Fassoulaki et al. (2002)51 7 Gabapentin, no 3 months after surgery, the incidence of chronic
pain, its severity, and the need for supplemental
analgesics were not affected by either
intervention. There was a report of increased
“burning” pain in the control group versus the
other 2 groups
Fassoulaki et al. (2005)52 7 Gabapentin and multimodal
regimen, yes
3 and 6 months after surgery, 18 of 22 (82%) and
12 of 21 (57%) of the controls reported chronic
pain versus 10 of 22 (45%) and 6 of 20 (30%) in
the treatment group. A significant difference was
evident at 3 months, but not 6 months
Moore et al. (2011)45 8 Gabapentin, no 3 months after surgery, the incidence of chronic
pain, its severity, and the need for supplemental
analgesics were similar between groups
Pesonen et al. (2011)53 8 Pregabalin, yes At 3 months after surgery, patients in the placebo
group (23%) experienced non-zero pain
significantly more often than patients in the
pregabalin group (4%)
Sen et al. (2009)48 7 Gabapentin, yes The severity of incisional pain was significantly less
in the gabapentin-treated group at 1, 3, and 6
months
Sen et al. (2009)47 8 Gabapentin, yes The severity of incisional pain was significantly less
in the gabapentin-treated group at 1, 3, and 6
months
Self-report measures
of disability/
physical function
Amr et al. (2010)46 7 Gabapentin N/A No self-report measures of disability performed
Brogly et al. (2008)50 6 Gabapentin N/A No self-report measures of disability performed
Burke et al. (2010)34 8 Pregabalin, yes The Roland Morris disability score at 3 months was
significantly lower in patients who received
pregabalin (2.7  2.4) than in those who received
placebo (5.6  4.8)
Buvanendran et al. (2010)31 9 Pregabalin, yes The KOOS–PS knee function score (0–100) was
improved in patients who received perioperative
pregabalin (12.4  5.5) versus placebo patients
with chronic pain (49.0  16.2) and an age-
matched nonchronic pain placebo
cohort (25.7  7.2)
(Continued)
outcomes presented in 6 of the 8 gabapentin trials. Among the
6 studies that could be included in meta-analysis, gabapentin
caused a moderate-to-large reduction in the development of
CPSP (pooled OR 0.52; 95% CI, 0.27 to 0.98; P  0.04).
Preventive Effects of Pregabalin on CPSP
Three studies examined the preventive effects of periop-
erative pregabalin administration on the incidence and
intensity of CPSP (Tables 2 and 3).31,34,53 All 3 studies
showed significant preventive analgesic effects in that
there was a reduced incidence of pain and/or lower
analgesic requirements at long-term follow-up, 2
months after surgery. Buvanendran et al.31 randomized
patients to receive a 300-mg preoperative dose of prega-
balin followed by a 14-day twice-a-day (BID) regimen of
pregabalin (50 mg to 150 mg) or placebo after total knee
arthroplasty.31 The Leeds Assessment of Neuropathic
Symptoms and Signs54 was used to diagnose the pres-
ence of chronic neuropathic pain at 3 and 6 months after
surgery. The results showed that 8.7% and 5.2% of
placebo-treated patients experienced chronic neuro-
pathic pain 3 and 6 months after surgery, respectively. In
contrast, not a single patient in the pregabalin-treated
group was diagnosed with chronic neuropathic pain at
either follow-up.31
Burke and Shorten34 randomly assigned patients to receive
either pregabalin (300 mg at 90 minutes preoperatively and
150mg at 12 and 24 hours postoperatively) (n 20) or placebo
(n  20) at corresponding times in a double-blind manner
while undergoing lumbar discectomy. The primary out-
come measure was a change in the intensity of pain as
measured by a visual analog scale from the preoperative
assessment to 3-month follow-up. Visual analog scale
pain scores were lower at 3 months (37.6  19.6 mm) in
treated patients than in controls (25.3  21.9 mm).34
Pesonen et al. randomly assigned 75 elderly patients (all
75 years or older) to receive either 150 mg of pregabalin
before surgery and 75 mg of pregabalin BID for 5 postop-
erative days or placebo.53 Elderly patients in this study who
received pregabalin consumed fewer supplemental analge-
sics in the acute hospital period and had lower confusion
assessment scores on postoperative day 1. The incidence of
pain during movement was significantly lower in the
pregabalin group 3 months after surgery.53 Table 4 presents
the odds ratios for the outcomes reported in the 3 prega-
balin trials. Within the 2 studies that could be included in
the meta-analysis, pregabalin caused a very large reduction
in the development of CPSP (pooled OR 0.09; 95% CI, 0.02
to 0.79; P  0.007).
Table 3. (Continued)
Outcome Study
Quality/
Delphi
score
2 agent/
preventive effects Postoperative outcome results*(P < 0.05)
Clarke et al. (2009)49 8 Gabapentin, no No difference between groups: “To what extent does
your hip arthroplasty site pain interfere with your
everyday activities?” Pain intensity was also
similar in both groups at 6 months with bending
knees to 90 degrees
Fassoulaki et al. (2002)51 7 Gabapentin N/A No self-report measures of disability performed
Fassoulaki et al. (2005)52 7 Gabapentin and multimodal
regimen N/A
No self-report measures of disability performed
Moore et al. (2011)45 8 Gabapentin, no Only 1 patient in each group reported that pain
limited his or her daily function
Pesonen et al. (2011)53 8 Pregabalin, yes No self-report measures of disability performed
Sen et al. (2009)48 7 Gabapentin, yes Daily activities were significantly less affected in the
gabapentin-treated patients at 1 and 3 months
after surgery, but not at 6 months. Unfortunately,
data were not provided, and the magnitude of this
difference cannot be determined
Sen et al. (2009)47 8 Gabapentin, no A smaller number of patients in the gabapentin-
treated group reported an impairment in daily
activities 1 month after surgery. No difference was
seen at 3 and 6 months after surgery
Functional outcome
measurement
Buvanendran et al. (2010)31 9 Pregabalin, yes Patients treated with pregabalin had greater active
knee flexion 30 days after surgery
Significant side
effects
Buvanendran et al. (2010)31 9 Pregabalin, yes Patients who received 300 mg of pregabalin
preoperatively followed by 50–150 mg of
pregabalin BID experienced greater postoperative
sedation and confusion
Moore et al. (2011)45 8 Gabapentin, no Patients receiving gabapentin were more likely to
report their sedation as severe (19%) than
patients receiving placebo (0%) within the first 24
hours postoperatively
Pesonen et al. (2011)53 8 Pregabalin, yes The CAM–ICU confusion test score was significantly
reduced in the placebo group on the first day after
extubation
BID  twice a day; CAM–ICU  the Confusion Assessment Method for Intensive Care Unit Patients; DN2  Neuropathic Pain Diagnostic Questionnaire;
KOOS–PS  Knee Osteoarthritis Outcome Score—Physical Function short form; N/A  not applicable; SCPB  superficial cervical plexus block; VAS  visual
analogue scale.
Functional Outcomes and Disability Assessment
Six of the 11 trials included a long-term functional outcome
measure or disability assessment.31,34,45,47–49 These studies
used self-report questionnaires to measure the impact of
perioperative gabapentin and pregabalin on daily function
in the long-term. The 4 gabapentin trials assessed this
outcome by asking the patients, “What impact does pain
currently have on your daily activities?”45,47–49
Four of the 6 trials found that perioperative gabapentin/
pregabalin administration improved long-term functional
outcomes. Two gabapentin trials reported that a single
1200-mg dose of gabapentin was associated with improved
daily functioning 1 month after inguinal herniorrhaphy47 and
1 and 3 months after total hysterectomy.48 Two pregabalin
trials31,34 used valid and reliable tools to measure postopera-
tive functional disability. Three months after lumbar discec-
tomy the Roland Morris disability score was significantly
lower in the patients who received perioperative pregabalin
(2.7  2.4) than in those who received placebo (5.6  4.8).34
Using scores from the Knee Osteoarthritis Outcome Score—
Physical Function Short-form (KOOS–PS),55 Buvanendran et
al.31 reported that patients who were diagnosed with chronic
pain at 6 months (all placebo treated) had significantly worse
KOOS–PS knee scores (49 16.2) than did pregabalin-treated
patients (12.4  5.5). The KOOS–PS knee scores of the
pregabalin-treated patients were also significantly better
when compared with an age-matched nonchronic pain pla-
cebo cohort (25.7  7.2).31
The remaining 2 gabapentin trials45,49 reported that a
single 600-mg dose of gabapentin did not affect functional
outcomes or disability 3 and 6 months after surgery.
DISCUSSION
We systematically reviewed the published literature on the
development of CPSP (2 months after surgery) after periop-
erative gabapentin or pregabalin administration. Our search
yielded 11 trials published between 2002 and 2011. Of the 11
trials published, 8 were perioperative gabapentin trials, 4 of
which (i.e., 50%) found that gabapentin decreased the inci-
dence of chronic pain that persisted for more than 2 months
after surgery. All pregabalin trials (3 of 3) demonstrated that
pregabalin decreased the incidence of CPSP, and 2 of those
trials also found an improvement in postsurgical patient
function. These findings in individual trials were confirmed
by our meta-analysis, which found that gabapentin and prega-
balin caused an overall moderate-to-large reduction in CPSP.
The randomized controlled trials included in this sys-
tematic review are of moderate to high quality (mean Delphi
score 7.5/9). Fifty percent of the gabapentin trials and 100%
of the pregabalin trials demonstrated a preventive effect with
respect to the incidence/intensity of chronic postsurgical pain.
This is compelling, but early, evidence suggesting that the
reduction in CPSP may be linked to the perioperative admin-
istration of these medications. However, there are several
shortcomings in the literature reviewed.
All 11 trials had small sample sizes and appeared to be
underpowered for the secondary outcomes related to the
incidence and severity of CPSP. The trial by Burke and
Shorten34 is the only one that powered the study, a priori,
to detect an effect on chronic postoperative pain 3 months
after surgery.34 Importantly, and in contrast to the other 10
studies, Burke and Shorten34 studied the magnitude of the
change from preoperative persistent lumbar back pain to
Table 4. Odds Ratios for Reported Outcomes Comparing Placebo-Treated Patients with Gabapentin- or
Pregabalin-Treated Patients
Study* Outcome
Odds ratio
(95% CI) P value Interpretation
Amr et al.46 Incidence of CPSP at 6 months 0.48 (0.16–1.43) 0.187 Gabapentin-treated at no lower risk than
placebo-treated
Brogly et al.50 Number of Patients with DN2
score 3 at 6 months
0.11 (0.01–0.99) 0.048 Gabapentin-treated at lower risk than
placebo-treated
Burke et al.34 Number of patients achieving a good
outcome on the RMDQ
0.15 (0.03–0.85) 0.031 Pregabalin-treated at lower risk of poor
functional outcome than placebo-treated
Buvanendran et al.31 CPSP at 3 months (S–LANS
score 12)
0.04 (0.003–0.76) 0.032 Pregabalin-treated at lower risk than placebo-
treated
CPSP at 6 months (S–LANS
score 12)
0.07 (0.00–1.33) 0.077 Pregabalin-treated at no lower risk than
placebo-treated
Clarke et al.49 CPSP at 6 months 1.15 (0.44–2.95) 0.779 Gabapentin-treated at no lower risk than
placebo-treated
Fassoulaki et al.51 Incidence of chronic pain at 3 months 0.78 (0.25–2.47) 0.671 Gabapentin-treated at no lower risk than
placebo-treated
Incidence of burning pain at 3 months 0.11 (0.01–1.03) 0.054 Gabapentin-treated at no lower risk than
placebo-treated
Fassoulaki et al.52 CPSP at 3 months 0.19 (0.04–0.72) 0.015 Gabapentin-treated at lower risk than
placebo-treated
CPSP at 6 months 0.19 (0.05–0.73) 0.084 Gabapentin-treated at lower risk than
placebo-treated
Moore et al.45 CPSP at 3 months 0.57 (0.09–3.61) 0.552 Gabapentin-treated at no lower risk than
placebo-treated
Pesonen et al.53 CPSP at 3 months 0.11 (0.01–0.91) 0.041 Pregabalin-treated at lower risk than placebo-
treated
CI  confidence interval; CPSP  chronic post surgical pain; DN2  Neuropathic Pain Diagnostic Questionnaire; RMDQ  Roland Morris Disability Questionnaire;
S–LANS  Leeds Assessment of Neuropathic Symptoms and Signs pain scale.
*Data from Sen et al.47,48 not shown in published article nor supplied upon request.
CPSP as a function of the drug intervention. The other 10
trials used patients without preexisting pain, and reported
the effects of the intervention in relation to the incidence
and severity of CPSP without an appropriate power calcu-
lation for this endpoint.
Overall, the meta-analysis found very promising
pooled effects of gabapentin and pregabalin; the magni-
tude of these effects, especially with respect to pregaba-
lin given the limited number of studies (OR 0.09), may be
clinically implausible. In addition, our analysis found
that publication bias might have exaggerated the re-
ported benefits of gabapentin and pregabalin. Conse-
quently, this meta-analysis, while promising, should not
be viewed as definitive.
Of the 8 gabapentin trials included in this review, 5 of the
studies used single-dose gabapentin 1 to 2 hours before
surgery.45,47–50 The 3 trials that used 1200 mg gabapentin
before surgery all reported that gabapentin reduced the
incidence and severity of chronic pain.47,48,50 The 2 trials that
used a single 600-mg gabapentin administration 2 hours
before surgery failed to show any reduction in the incidence
or severity of CPSP at 3 and 6 months after surgery.45,49 This
is limited evidence to suggest that using a high preoperative
dose of gabapentin (i.e., 1200 mg) is more effective than using
low preoperative doses for the prevention of CPSP. Gabap-
entin at higher doses in the preoperative period may have a
greater effect on blunting the peripheral and central sensiti-
zation processes that occur during surgery.
Of the 3 remaining gabapentin studies (all the studies
continued gabapentin into the postoperative time period),
only 152 demonstrated a significant pain reduction that per-
sisted for 2 or more months after surgery. It has been well
documented that the absorption profile of gabapentin in
humans is inconsistent due to the active and saturable
-amino acid transport system.56 Thus, the bioavailability of
any given dose varies from 35% to 90%.56 Without plasma
samples, one cannot confirm therapeutic drug concentra-
tions of gabapentin; no trial identified in this systematic
review tested plasma levels to confirm therapeutic levels.
The results from this systematic review suggest that
pregabalin may have a more promising and effective role
in the prevention of CPSP syndromes, given its more
reliable absorption profile (90% bioavailability of a
single dose). Finally, although the results from this
review suggest that higher doses of the -2- ligands
may produce greater antinociceptive efficacy, higher
doses also unreliably increase somnolence and confusion
in the clinical setting.57,58 It is not uncommon to have
patients who have been given 1200 mg of gabapentin 1 to
2 hours before surgery present in the postoperative care
unit completely awake, while others are almost com-
pletely somnolent.
The factors involved in the development of CPSP are not
well understood. Several observational studies have outlined
highly variable rates of CPSP after total knee arthroplasty,59
total hip arthroplasty,59,60 cardiac surgery,61 mastectomy,62
inguinal hernia,63 cholecystectomy,64 and thoracotomy65,66
populations. Future studies need to elaborate on the impact
that CPSP syndromes have on patient function. To that end,
recommendations have been made for the assessment of core
measures and domains in clinical trials focused on chronic
pain.67 These recommendations include psychological, emo-
tional, and physical variables in addition to those routinely
assessed in perioperative anesthesia trials (i.e., pain incidence
and severity, and analgesic consumption). Assessment of
additional domains of physical function and the experience of
pain during those functional activities may help to identify
patient-related factors, which may impact the recovery pro-
cess after surgery; these factors may also be associated with
the development of CPSP.
Multimodal analgesic regimens involve the use of different
classes of analgesic drugs to provide superior pain relief at
rest and with movement, reduce opioid consumption, and
reduce analgesic-related adverse effects.68 Using multimodal
perioperative acute pain strategies (i.e., different classes of
medications that act on different nociceptive afferent and
efferent pathways in the perioperative setting) has become the
standard of care for many surgical populations.68 These
strategies have demonstrated good acute pain reductions
and opioid sparing in the short term.69,70 More data that
assess these regimens at preventive endpoints are
needed. One study in this review compared a compre-
hensive multimodal perioperative regimen to placebo
and found that patients treated with the multimodal
regimen had a decreased incidence and severity of CPSP
and used less supplemental analgesics at 3 and 6 months.52 The
obvious limitation with this study and other similar studies is
the inability to determine to what extent each medication
affected the transition to chronic pain.
The field of human pain genetics is in its infancy. One
review summarized the rapidly accumulating evidence from
animal models of CPSP and studies in human twins, which
showed that chronic pain was a complex heritable trait.2
Several studies have recently reported on polymorphisms in
certain genes that predispose carriers to transition to pain
chronicity.71–73 Burke and Shorten34 attempted to link their
findings to known human genetic polymorphisms associated
with pain. They did not report significant associations with
GCH1 or OPRM1 in the 38 patients followed. However, there
were several shortcomings to the genetic data presented,
including too few patients, the absence of a detailed descrip-
tion of the assays/methods used with respect to gene map-
ping, and appropriate input from genetic statisticians. This
information is essential for future researchers attempting to
replicate and validate positive genetic findings.
Novel Postulated Mechanisms of Action
of Gabapentinoids
The proposed mechanism of action of gabapentin and prega-
balin is believed to be the selective inhibitory binding to the
2 subunit of voltage-dependent calcium channels in acti-
vated neurons.74 The binding of gabapentin to the 2 subunit
reduces the expression of voltage-dependent calcium
channels.75 A point mutation in the 2 type 1 subunit
(R217A) prevents the binding of gabapentin to the cal-
cium channel.76 The analgesic properties of both gabap-
entin and pregabalin are greatly reduced in mice ex-
pressing this point mutation.77 The mutation also
prevents the ability of gabapentin to reduce calcium
channel expression.75
Several lines of evidence suggest that this high-affinity site
contributes to, but may not fully account for, the analgesic
properties of gabapentin. The increased expression of the 2
subunit that occurs in animal models of hyperalgesia is
not a prerequisite for the short-term analgesic actions of
gabapentin.78 In addition, a comparison of the antinoci-
ceptive properties of gabapentin and stereoisomeric ana-
logues of gabapentin revealed a stereospecific analgesic
effect of some but not all of the gabapentin analogues;79
but surprisingly, some of the gabapentin analogues with
high affinity for the 2 subunit did not have antinoci-
ceptive properties.
Some evidence suggests that the 2 subunit also regu-
lates synaptogenesis through mechanisms that are inde-
pendent of Ca2 channel function.80 Specifically, the 2
subunit is a receptor for thrombospondins, proteins that are
secreted by astrocytes and promote synapse formation.81
Gabapentin disrupts the interaction between thrombospon-
dins and the 2 subunit, resulting in decreased synapse
formation.80 The disruption of 2 subunit-mediated syn-
aptogenesis by gabapentin may also contribute to the
analgesic effects of gabapentin and pregabalin, particularly
for the treatment of chronic pain.
Gabapentin and pregabalin have been proposed to act
through a wide variety of mechanisms beyond inhibiting
the actions of the 2 subunit protein. Gabapentin
inhibits glutamate release, increases the activity of
N-methyl-d-aspartate receptors, inhibits the activity of
voltage-gated sodium channels, and enhances the activ-
ity of voltage-gated potassium channels.82 Additionally,
prolonged exposure to gabapentin can increase the am-
plitude of a tonic inhibitory GABAergic conductance83
that may regulate pain processes.84 However, it remains
to be determined whether these mechanisms contribute
to the analgesic effects of gabapentin and pregabalin.
CONCLUSIONS
Our systematic review found promising results for gabapen-
tin with respect to the reduction of CPSP. Commonalities
among the 4 positive studies should be explored in future
trials given that there appears to be emerging basic science
data to support its plausibility with respect to the prevention
of CPSP. The 3 pregabalin trials included in this systematic
review reported even greater promise in preventing the
conversion from acute pain to CPSP. The improved absorp-
tion profile of pregabalin may be a primary reason for its
improved efficacy. The study of the antecedent patient-related
factors that may also predict the development of CPSP is
important, and future studies should expand current outcome
domains. Appropriate measures of psychological and physi-
cal functioning should be included, along with measures of
chronic pain incidence and severity. Given the limited
number of studies identified in our review, the clinical
heterogeneity of the trials identified, and the suggestion
that a publication bias may be present, future well-
designed, appropriately powered studies are needed to
clarify whether gabapentin and pregabalin have a peri-
operative role in the prevention of CPSP.
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APPENDIX 1. Search Terms
Pregabalin or gabapentin-
related terms
Perioperative/preemptive/
preventive and related terms
Pregabalin exp perioperative care/
lyrica intraoperative care/
Gabapentin postoperative care/
60142-96-3.rn. (registry
number)
preoperative care/
neurontin exp Anesthesia Recovery Period/
((alpha adj2 delta) or
(alpha2delta.mp) AND
exp Calcium channel
blockers/
perioperat*
peri-operat*
peroperat*
postop*
Chronic pain-related terms post-op*
exp chronic diseases/ AND
exp pain/
preoperat*
(chronic* adj4 pain*) pre-operat*
intraoperat*
intra-operat*
(before adj2 surgery)
(before adj2 operat*4)
(prior adj2 surgery)
(prior adj2 operat*4)
operation?
operative*
(surgery or surgeries or surgeon? or
surgical*)
su.fs. (surgery floating subheading)
exp surgical procedures, operative/
exp Anesthesiology/
anesthes*
anaesthes*
exp Anesthesia/
anesthe*.jn,in. (journal or institution)
anaesthe*.jn,in. (journal or
institution)
preincision?
pre-incision?
postincision?
post-incision?
preemptive*
pre-emptive*
preventive*
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